Allarity Therapeutics, Inc. (ALLR): Nasdaq/NYSE listing notice — Allarity Therapeutics receives Nasdaq delisting notice; additional $350K note from 3i

Allarity Therapeutics, Inc.

Nasdaq notified the company on April 11, 2023 that it failed to meet extension terms for minimum $10M equity rule; delisting set for April 20 unless appeal.
Company reported stockholders' equity of ~$8.0M as of June 30, 2022, below the $10M continued listing requirement.
Entered first amendment allowing additional note purchases from 3i, LP; on April 11, 3i purchased a $350,000 secured promissory note.
Total principal outstanding under the notes is $2,666,640; new notes bear 5% interest, mature Jan 1, 2024, and are secured by all assets.
Company intends to appeal the delisting determination to Nasdaq.

item 1.01 item 2.03 item 3.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Allarity Therapeutics, Inc. incurred convertible notes of $350,000 with 3i, LP at 5% per annum maturing January 1, 2024.

Instrument: convertible notes
Principal: $350,000
Counterparty: 3i, LP
Rate: 5% per annum
Maturity: January 1, 2024
Event: incurrence

Exact text from the filing

On April 11, 2023, 3i purchased an additional note for an aggregate amount of $350,000, which purchase price was paid for in cash. Each note issued under the Purchase Agreement matures on January 1, 2024, carries an interest rate of at 5% per annum, and is secured by all of the Company’s assets pursuant to a security agreement

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Allarity Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5450(b)(1)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5450(b)(1)(A)

Exact text from the filing

April 11, 2023, we received notification from the Nasdaq Listing Qualifications staff that it has determined that the Company did not meet the terms of the extension. Specifically, the Company did not complete its proposed transactions and was unable to file a Form 8-K by the April 10, 2023 deadline, evidencing compliance with the Rule. As a result, the Company’s securities will be delisted from The Nasdaq Global Market. In that regard, unless the Company requests an appeal of such determination, trading of the Company’s Common Stock will be suspended at the opening of business on April 20, 20

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Allarity Therapeutics, Inc. amended First Amendment to the Secured Note Purchase Agreement with 3i, LP valued at aggregate principal amount of $2,666,640 (effective 2023-04-10).

Action: amendment
Agreement: notes offering
Counterparty: 3i, LP
Value: aggregate principal amount of $2,666,640
Effective: 2023-04-10

Exact text from the filing

Allarity Therapeutics, Inc. (“we,” “our,” or the “Company”) entered into a First Amendment to the Secured Note Purchase Agreement dated April 10, 2023 (the “First Amendment”) with 3i, LP (“3i”), the sole holder of our Series A Convertible Preferred Stock

View on SEC.gov

100 debt financings filed in the last 30 days. Browse all debt financings →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-029177

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.